FDB (First Databank, Inc.), the leading provider of drug knowledge that helps healthcare professionals make precise medication decisions, will shine a spot...
ORIC Pharmaceuticals, Inc. a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, announced ...
Novita Pharmaceuticals, Inc. ("Novita"), a privately held, clinical-stage pharmaceutical company dedicated to developing novel cancer drugs through i...
HBM Alpha Therapeutics (HBMAT), Inc., an innovative biotechnology company incubated by Harbour BioMed, announced a strategic collaboration and license...
Telix Pharmaceuticals Limited announces that the United States (U.S.) Food and Drug Administration (FDA) has accepted the Biologics License...
Akeso, Inc. ("Akeso" or the "Company") announced that its partner on ivonescimab, Summit Therapeutics Inc. has entered into a clinical trial collabor...
Bristol Myers Squibb announced that the U.S. Food and Drug Administration (FDA) has accepted the supplemental biologics license application (sBLA) for...
Regeneron Pharmaceuticals, Inc. announced updated data for the investigational gene therapy DB-OTO from the Phase 1/2 CHORD trial in 12 children who have p...
Johnson & Johnson announced data from the Phase 3 ASTRO study of TREMFYA® (guselkumab) subcutaneous (SC) induction therapy in adults with...
Chime Biologics, a leading global CDMO that enables its partners success in biologics, announced its continued collaboration with Mabgeek in adva...
Innovent Biologics, Inc., a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment o...
Ionis Pharmaceuticals, Inc. announced that it will present additional data from the pivotal Phase 3 OASIS and OASISplus studies, as well as three yea...
Bristol Myers Squibb announced the final analysis of overall survival (OS) from the Phase 3 CheckMate -816 study, which evaluated Opdivo (ni...
GSK plc announced that the China National Medical Products Administration has accepted for review the new drug application for the use of Nucala ...
© 2025 Biopharma Boardroom. All Rights Reserved.
